8 active shortage notices across 4 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Italy | critical | 4 | 1 Dec 2025 | 1 Apr 2026 | AIFA |
| United States | high | 1 | 29 Aug 2025 | — | FDA MedWatch |
| European Union | high | 1 | 17 Jan 2025 | — | EMA |
| Belgium | medium | 2 | 1 Dec 2025 | 1 Apr 2026 | FAMHP |
Yes. As of the latest regulator updates, Bevacizumab has 8 active shortage notices across 4 countries (Italy, United States, European Union, Belgium). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Bevacizumab shortages to unexpected increases in demand, manufacturing problems, regulatory action. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 1 Apr 2026 to 1 Apr 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Rituximab · Elotuzumab · Bevacizumab (Avastin) Injection · Avastin · Daratumumab · Trastuzumab
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.